Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience

Dupilumab, a fully human anti-interleukin-4/interleukin-13 monoclonal antibody, has shown efficacy in many aspects of Type-2 severe asthma management. Currently, we lack real-life studies addressing the achievment of clinical remission in patients treated with this biologic.

Source: Respiratory Medicine - July 6, 2023 Category: Respiratory Medicine Authors: Andrea Portacci, Ilaria Iorillo, Vitaliano Nicola Quaranta, Leonardo Maselli, Ernesto Lulaj, Enrico Buonamico, Silvano Dragonieri, Giovanna Elisiana Carpagnano Tags: Original Research Source Type: research